The therapeutic effect of NRF2 activator, ezetimibe, in cardiac cachexia
Fundamental & Clinical Pharmacology · 2024
DOI: 10.1111/fcp.13029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Ruju Vashi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy, Nirma University, Ahmedabad, India. Hauptthemen laut MEDLINE: Cachexia, Ezetimibe, NF-E2-Related Factor 2, Mice, Inbred BALB C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben.
Abstract (Originalsprache)
Introduction
Heart failure (HF) is caused by functional and structural irregularity leading to impaired ejection or filling capacity of the heart. HF leads to chronic inflammatory conditions in the heart leads to weight loss, anorexia, and muscle atrophy known as cachexia. The present study was carried out to investigate the role of Ezetimibe, an NRF2 activator, in cardiac cachexia and to develop a treatment strategy for cardiac cachexia.
Method
Balb/c mice of either sex at 6–8 weeks of age were given 2 mg/kg of doxorubicin in 0.9% sodium chloride solution intraperitoneally (i.p.) for the alternate days for the first week and then once a week for the next 4 weeks. After induction of cardiac atrophy, treatment with Ezetimibe (1.5 mg/kg, p.o ) was given for the next 4 weeks.
Result
In the cardiac cachectic animals, a significant decrease in body weight, food, and water intake was observed. Cardiac cachectic animals showed a significant increase in serum glucose, total cholesterol, LDL, triglyceride, VLDL, CK‐MB, LDH, and CRP levels. Cardiac atrophic index, heart weight to body weight ratios (HW/BW), right ventricular weight to heart weight ratios (RV/HW), and left ventricular weight to heart weight ratios (LV/HW), were significantly decreased in cardiac cachectic animals. The weights of the skeletal muscles such as EDL, gastrocnemius, soleus, tibialis anterior, and quadriceps muscles, and the weight of adipose tissue such as subcutaneous, visceral, perirenal, and brown adipose tissue were significantly decreased in the cardiac cachectic group relative to the normal group. Treatment with ezetimibe improves body weight, food intake, and water intake. Ezetimibe decreases serum glucose, total cholesterol, LDL, triglyceride, VLDL, CK‐MB, LDH and CRP levels. Cardiac atrophic markers such as HW/BW, RV/HW, and LV/HW were improved. The weight of skeletal muscles and adipose tissue was increased after treatment with ezetimibe.
Conclusion
Our data showed that the NRF2 activator, Ezetimibe produces a beneficial effect on cardiac cachexia in the doxorubicin‐induced cardiac cachexia model. Ezetimibe was successful to reduce the levels of inflammatory cytokines, ameliorate the effects on cardiac muscle wasting, lipid levels, fat tissues, and skeletal muscles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacy, Nirma University, Ahmedabad, India.
- National Forensic Sciences University, Gandhinagar, India.
ORCID-Profile: Mit Joshi, Bhoomika M Patel
Zitieren
APA
Vashi, R., Joshi, M., & Patel, B. M. (2024). The therapeutic effect of NRF2 activator, ezetimibe, in cardiac cachexia. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.13029
Vancouver
Vashi R, Joshi M, Patel BM. The therapeutic effect of NRF2 activator, ezetimibe, in cardiac cachexia. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.13029
BibTeX
@article{Vashi2024,
author = {Vashi, Ruju and Joshi, Mit and Patel, Bhoomika M},
title = {The therapeutic effect of NRF2 activator, ezetimibe, in cardiac cachexia},
journal = {Fundamental & Clinical Pharmacology},
year = {2024},
doi = {10.1111/fcp.13029}
}
EUVIMED